ZA200307678B - Modified ciliary neurotrophic factor (CNTF) with reduced immunogenicity. - Google Patents
Modified ciliary neurotrophic factor (CNTF) with reduced immunogenicity. Download PDFInfo
- Publication number
- ZA200307678B ZA200307678B ZA200307678A ZA200307678A ZA200307678B ZA 200307678 B ZA200307678 B ZA 200307678B ZA 200307678 A ZA200307678 A ZA 200307678A ZA 200307678 A ZA200307678 A ZA 200307678A ZA 200307678 B ZA200307678 B ZA 200307678B
- Authority
- ZA
- South Africa
- Prior art keywords
- amino acid
- molecule
- peptide
- modified
- cntf
- Prior art date
Links
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 title claims description 47
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 title claims description 46
- 230000005847 immunogenicity Effects 0.000 title claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 112
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 61
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 56
- 108090000623 proteins and genes Proteins 0.000 claims description 44
- 102000004169 proteins and genes Human genes 0.000 claims description 43
- 125000000539 amino acid group Chemical group 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 39
- 230000027455 binding Effects 0.000 claims description 38
- 238000006467 substitution reaction Methods 0.000 claims description 31
- 150000001413 amino acids Chemical class 0.000 claims description 24
- 229920001184 polypeptide Polymers 0.000 claims description 23
- 108091054438 MHC class II family Proteins 0.000 claims description 22
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 19
- 230000004071 biological effect Effects 0.000 claims description 19
- 102000043131 MHC class II family Human genes 0.000 claims description 18
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims description 14
- 230000004075 alteration Effects 0.000 claims description 13
- 230000001225 therapeutic effect Effects 0.000 claims description 12
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims description 10
- 230000002163 immunogen Effects 0.000 claims description 10
- 238000001727 in vivo Methods 0.000 claims description 9
- 238000007792 addition Methods 0.000 claims description 8
- 238000012217 deletion Methods 0.000 claims description 8
- 230000037430 deletion Effects 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 8
- 238000000126 in silico method Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000009467 reduction Effects 0.000 claims description 6
- 108020004511 Recombinant DNA Proteins 0.000 claims description 5
- 230000006870 function Effects 0.000 claims description 5
- 239000003446 ligand Substances 0.000 claims description 5
- 230000009149 molecular binding Effects 0.000 claims description 5
- 238000004166 bioassay Methods 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 230000004048 modification Effects 0.000 claims description 4
- 238000012986 modification Methods 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 230000002209 hydrophobic effect Effects 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 238000012360 testing method Methods 0.000 claims description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000005070 sampling Methods 0.000 claims description 2
- 230000001886 ciliary effect Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 description 10
- 101000993364 Homo sapiens Ciliary neurotrophic factor Proteins 0.000 description 9
- 150000001408 amides Chemical class 0.000 description 8
- 241000282412 Homo Species 0.000 description 7
- 108091008874 T cell receptors Proteins 0.000 description 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 6
- 230000004913 activation Effects 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 102000015636 Oligopeptides Human genes 0.000 description 4
- 108010038807 Oligopeptides Proteins 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 108020001756 ligand binding domains Proteins 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 108010078049 Interferon alpha-2 Proteins 0.000 description 2
- 102100039350 Interferon alpha-7 Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 108010010378 HLA-DP Antigens Proteins 0.000 description 1
- 102000015789 HLA-DP Antigens Human genes 0.000 description 1
- 108010062347 HLA-DQ Antigens Proteins 0.000 description 1
- 101000620653 Homo sapiens Serine/threonine-protein phosphatase 5 Proteins 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 102100022346 Serine/threonine-protein phosphatase 5 Human genes 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01105089 | 2001-03-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200307678B true ZA200307678B (en) | 2004-08-31 |
Family
ID=8176647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200307678A ZA200307678B (en) | 2001-03-02 | 2003-10-01 | Modified ciliary neurotrophic factor (CNTF) with reduced immunogenicity. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20040087503A1 (hu) |
| EP (1) | EP1379655A2 (hu) |
| JP (1) | JP2004529629A (hu) |
| KR (1) | KR20030081480A (hu) |
| CN (1) | CN1494593A (hu) |
| BR (1) | BR0207705A (hu) |
| CA (1) | CA2439682A1 (hu) |
| HU (1) | HUP0303310A2 (hu) |
| MX (1) | MXPA03007839A (hu) |
| PL (1) | PL362704A1 (hu) |
| RU (1) | RU2003129069A (hu) |
| WO (1) | WO2002070698A2 (hu) |
| ZA (1) | ZA200307678B (hu) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050064555A1 (en) * | 2003-07-09 | 2005-03-24 | Xencor, Inc. | Ciliary neurotrophic factor variants |
| WO2005033137A1 (en) * | 2003-09-30 | 2005-04-14 | Regeneron Pharmaceuticals, Inc. | Modified ciliary neurotrophic factor polypeptides with reduced antigenicity |
| US8592374B2 (en) | 2007-03-16 | 2013-11-26 | Research Foundation For Mental Hygiene, Inc. | Neurotrophic peptides |
| EP2009103A1 (en) * | 2007-03-16 | 2008-12-31 | Ebewe Pharma Ges.m.b.H. Nfg. KG | Neurotrophic peptides |
| US8252897B2 (en) * | 2007-06-21 | 2012-08-28 | Angelica Therapeutics, Inc. | Modified toxins |
| EP2268297A4 (en) * | 2008-02-29 | 2011-11-16 | Angelica Therapeutics Inc | MODIFIED TOXINS |
| DE102011104822A1 (de) | 2011-06-18 | 2012-12-20 | Christian-Albrechts-Universität Zu Kiel | Ciliary-Neutrophic-Factor-Varianten |
| CA2902905A1 (en) | 2013-03-15 | 2014-09-25 | Claude Geoffrey Davis | Modified toxins |
| JP6840668B2 (ja) * | 2014-11-14 | 2021-03-10 | ディ.イー.ショー リサーチ, エルエルシーD.E.Shaw Research, Llc | 結合された粒子間の相互作用の抑制 |
| WO2018106790A1 (en) * | 2016-12-06 | 2018-06-14 | The Board Of Trustees Of The Leland Stanford Junior University | Ciliary neurotrophic factor receptor ligand-binding agents and methods of using the same |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5593857A (en) * | 1991-08-23 | 1997-01-14 | Scios Inc. | Production of homogeneous truncated CNTF |
| AU2925392A (en) * | 1991-11-11 | 1993-06-15 | Fidia S.P.A. | Synthesis and purification of truncated and mutein forms of human ciliary neuronotrophic factor |
| AU1282895A (en) * | 1993-12-29 | 1995-07-17 | Sumitomo Pharmaceuticals Company, Limited | Novel human ciliary neurotrophic factor |
| IT1288388B1 (it) * | 1996-11-19 | 1998-09-22 | Angeletti P Ist Richerche Bio | Uso di sostanze che attivano il recettore del cntf ( fattore neurotrofico ciliare) per la preparazione di farmaci per la terapia |
| JP2003507393A (ja) * | 1999-08-13 | 2003-02-25 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 改変された毛様体神経栄養因子、それらを作製する方法およびそれらの使用方法 |
-
2002
- 2002-02-27 CA CA002439682A patent/CA2439682A1/en not_active Abandoned
- 2002-02-27 CN CNA028058666A patent/CN1494593A/zh active Pending
- 2002-02-27 RU RU2003129069/13A patent/RU2003129069A/ru not_active Application Discontinuation
- 2002-02-27 HU HU0303310A patent/HUP0303310A2/hu unknown
- 2002-02-27 KR KR10-2003-7011480A patent/KR20030081480A/ko not_active Application Discontinuation
- 2002-02-27 WO PCT/EP2002/002084 patent/WO2002070698A2/en not_active Application Discontinuation
- 2002-02-27 EP EP02724185A patent/EP1379655A2/en not_active Withdrawn
- 2002-02-27 US US10/469,837 patent/US20040087503A1/en not_active Abandoned
- 2002-02-27 MX MXPA03007839A patent/MXPA03007839A/es unknown
- 2002-02-27 PL PL02362704A patent/PL362704A1/xx unknown
- 2002-02-27 JP JP2002570723A patent/JP2004529629A/ja not_active Withdrawn
- 2002-02-27 BR BR0207705-1A patent/BR0207705A/pt not_active IP Right Cessation
-
2003
- 2003-10-01 ZA ZA200307678A patent/ZA200307678B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2003129069A (ru) | 2005-04-20 |
| US20040087503A1 (en) | 2004-05-06 |
| KR20030081480A (ko) | 2003-10-17 |
| CN1494593A (zh) | 2004-05-05 |
| EP1379655A2 (en) | 2004-01-14 |
| PL362704A1 (en) | 2004-11-02 |
| CA2439682A1 (en) | 2002-09-12 |
| MXPA03007839A (es) | 2003-12-08 |
| JP2004529629A (ja) | 2004-09-30 |
| WO2002070698A3 (en) | 2003-11-20 |
| HUP0303310A2 (hu) | 2003-12-29 |
| WO2002070698A2 (en) | 2002-09-12 |
| BR0207705A (pt) | 2004-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20040072291A1 (en) | Modified human brain-derived neutrophic factor (bdnf) with reduced immunogenicity | |
| ZA200307678B (en) | Modified ciliary neurotrophic factor (CNTF) with reduced immunogenicity. | |
| WO2002062833A2 (en) | Modified leptin with reduced immunogenicity | |
| US20040063917A1 (en) | Modified erythropoietin (epo) with reduced immunogenicity | |
| EP1366074B1 (en) | Modified granulocyte macrophage colony stimulating factor (gm-csf) with reduced immunogenicity | |
| US20040076991A1 (en) | Modified interleukin-1 receptor antagonist(il-1ra) with reduced immunogenicity | |
| US20040121443A1 (en) | Modified protamine with reduced immunogenicity | |
| EP1392731B1 (en) | Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity | |
| US20040071688A1 (en) | Modified thrombopoietin with reduced immunogenicity | |
| CA2437270A1 (en) | Modified keratinocyte growth factor (kgf) with reduced immunogenicity | |
| ZA200308061B (en) | Modified insulin with reduced immunogenicity. | |
| ZA200306933B (en) | Modified interleukin-1 receptor antagonist (IL-1RA) with reduced immunogenicity. | |
| ZA200306926B (en) | Modified leptin with reduced immunogenicity. | |
| ZA200306934B (en) | Modified Keratinocyte growth factor (KGF) with reduced immunogenicity. | |
| ZA200306931B (en) | Modified granulocyte colony stimulating factor (G-CSF) with reduced immunogenicity. | |
| ZA200306924B (en) | Modified human brain-derived neutrophic factor (BDNF) with reduced immunogenicity. | |
| ZA200306930B (en) | Modified erythropoietin (EPO) with reduced immunogenecity. | |
| AU2002238530A1 (en) | Modified human brain-derived neutrophic factor (BDNF) with reduced immunogenicity | |
| AU2002242715A1 (en) | Modified protamine with reduced immunogenicity | |
| AU2002256686A1 (en) | Modified insulin with reduced immunogenicity | |
| AU2002257579A1 (en) | Modified granulocyte colony stimulating factor (G-CSF) with reduced immunogenicity | |
| AU2002250891A1 (en) | Modified leptin with reduced immunogenicity | |
| AU2002229744A1 (en) | Modified interleukin-1 receptor antagonist (IL-1RA) with reduced immunogenicity | |
| AU2002249180A1 (en) | Modified keratinocyte growth factor (KGF) with reduced immunogenicity | |
| AU2002250889A1 (en) | Modified erythropoietin (EPO) with reduced immunogenicity |